Third, increased CRP might reduce nitric oxide bioavailability via decreasing urinary excretion of cyclic guanosine monophosphate and activating NADPH oxidase, which could aggravate hypertension and thus MetS [34, 35]. The gene discussed is CRP; the disease is hypertensive disorder.